A Study of TCR-Redirected T Cell Infusion in Subject With Recurrent HBV-related HCC Post Liver Transplantation

Recurrent Hepatocellular Carcinoma Clinical Trial

Official title:

A Phase I Study T Cell Receptor-Redirected T Cells Infusions in Subjects With Recurrent HBV-Related Hepatocellular Carcinoma in Post Liver Transplantation

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT02719782
• Other study ID #: LTCR-HCC-2-1
• Status: Recruiting
• Phase: Phase 1
• Start date: July 2, 2015
• Est. completion date: December 2019

Study information

• Verified date: November 2018
• Source: Lion TCR Pte. Ltd.
• Contact: Grace Khoo Koay
• Phone: (65) 69260818
• Email: clinicaltrials[@]liontcr.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

Hepatocellular carcinoma (HCC) recurrence rate is high among liver transplant patients, while treatment measures are limited. This study plans to recruit 10 patients with Hepatitis B virus (HBV) related HCC who underwent liver transplantation and are confirmed to have recurrent HCC. The objective of the study is to assess the safety, tolerability and effectiveness of the HBV specific T cell receptor (HBV/TCR) redirected T cell in the target population.

Description:

This is a phase I, single armed and open labelled trial in patients with recurrent HBV related HCC after liver transplantation. Subjects who meet eligibility criteria will receive escalating doses of HBV specific T cell receptor (TCR-T) on Day 1, Day 8, Day 15 and Day 22 of the first 28-day treatment cycle, followed by every 2-week dosing on Day 1, Day 15, Day 29 and Day 43 of repeated cycle. A 21-day treatment break will be given between each cycle. Treatment will be continued until disease progression unless otherwise specified per investigator's discretion. Subjects will be followed up post treatment for safety monitoring, including monthly follow up for the first three month and every 2-monthly follow up up to 24 months post treatment.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 10
• Est. completion date: December 2019
• Est. primary completion date: May 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 21 Years to 65 Years

Eligibility

Inclusion Criteria:

• Diagnosis as hepatocellular carcinoma (HCC)

• Underwent liver transplantation and confirmed recurrent HCC post operation

• Seropositive for hepatitis B surface antigen

• No major post-operative complication

• Life expectancy of at least 12 weeks

• Ability to provide informed consent

• Ability to comply with study procedures

• HLA profile matching with HLA-class I restriction element of the available T cell receptors

Exclusion Criteria:

• Administration of any other cell therapy, including NK, CIK, DC, CTL, CAR-T, stem cells or combined therapy of the kind within 3 months prior to enrolment

• Second primary malignancy that is clinically detectable at the time of consideration for study enrolment

• Likelihood to require steroid treatment during the period of the clinical trial

• Any other concurrent liver infections such as hepatitis A, C or D infection

• Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection

• Known Central Nervous System tumours including metastatic brain disease.

• Any condition that is unstable or which could jeopardise the safety of the patient and his/her compliance in the study

• Patients with reproductive potential who tested positive for serum or urine pregnancy test result within 14 days prior to enrolment.

Related Conditions & MeSH terms

• Carcinoma
• Carcinoma, Hepatocellular
• Recurrent Hepatocellular Carcinoma

Intervention

Biological:
• Biological: TCR-T
Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR

Locations

Country	Name	City	State
China	Third Affiliated Hospital of Sun Yat-sen University	Guangzhou	Guangdong

Sponsors (3)

Lead Sponsor	Collaborator
Lion TCR Pte. Ltd.	Agency for Science, Technology and Research, Third Affiliated Hospital, Sun Yat-Sen University

Country where clinical trial is conducted

China, 

References & Publications (3)

Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss H, Bertoletti A. Engineering virus-specific T cells that target HBV infected hepatocytes and hepatocellular carcinoma cell lines. J Hepatol. 2011 Jul;55(1):103-10. doi: 10.1016/j.jhep.2010.10.025. Epub 2010 Nov 23. — View Citation

Koh S, Shimasaki N, Suwanarusk R, Ho ZZ, Chia A, Banu N, Howland SW, Ong AS, Gehring AJ, Stauss H, Renia L, Sällberg M, Campana D, Bertoletti A. A practical approach to immunotherapy of hepatocellular carcinoma using T cells redirected against hepatitis B virus. Mol Ther Nucleic Acids. 2013 Aug 13;2:e114. doi: 10.1038/mtna.2013.43. — View Citation

Qasim W, Brunetto M, Gehring AJ, Xue SA, Schurich A, Khakpoor A, Zhan H, Ciccorossi P, Gilmour K, Cavallone D, Moriconi F, Farzhenah F, Mazzoni A, Chan L, Morris E, Thrasher A, Maini MK, Bonino F, Stauss H, Bertoletti A. Immunotherapy of HCC metastases with autologous T cell receptor redirected T cells, targeting HBsAg in a liver transplant patient. J Hepatol. 2015 Feb;62(2):486-91. doi: 10.1016/j.jhep.2014.10.001. Epub 2014 Oct 13. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	1-year PFS (progression free survival) which is measured by the number of patients with stable disease after 1 year, using mRECIST		Start of treatment until disease progression, median 6 months
Primary	Safety of the TCR-T treatment		Start of treament until 1 month after last treatment
Secondary	Efficacy of induction of tumor specific T cell responses as measured by the persistence of HBV specific T cells in peripheral blood samples at several time points following adoptive transfer		Start of treatment until disease progression, and subsequent follow up up to 24 months post treatment
Secondary	Systemic release of inflammatory cytokines after administration of transduced T cells compared to baseline		Start of treatment until disease progression, and subsequent follow up up to 24 months post treatment